Comparison of US and European Guidelines

Oral Antiplatelet Therapy in Primary PCI/STEMI

GP IIb/IIIa Inhibitors in Primary PCI/STEMI

EUROMAXBleeding Outcomes at 30 d

HORIZONS-AMIBleeding Outcomes at 30 d in a Primary PCI

Population

CHAMPION PHOENIX Primary Efficacy Outcomes at 48 h, MITT

Anticoagulation in Primary PCI/STEMI

FUTURA/OASIS 8

Oral Antiplatelet Therapy in Non-ST Elevation ACS

CHARISMABleeding End Points by Baseline Daily Aspirin

Dose

CURRENTEfficacy and Bleeding by Aspirin Dose

EARLY-ACSBleeding Outcomes at 30 days

GP IIb/IIIa Inhibitors in Primary PCI/Non-ST-segment Elevation ACS

PLATO SubanalysisEfficacy and Safety End Points

Anticoagulation in Non-ST-segment Elevation ACS

OASIS 5 -- Cumulative Risk of Death, MI, or Refractory Ischemia

The Future for ACS Management?

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)